CG Oncology, Inc. is a clinical-stage biotechnology firm focused on developing groundbreaking cancer therapies, particularly through its lead product, CG0070, an oncolytic virus therapy designed for non-muscle invasive bladder cancer. The company is well-positioned to meet significant unmet medical needs in oncology, emphasizing the potential to improve patient outcomes and transform treatment approaches. With a robust proprietary technology platform and a commitment to advancing clinical trials and securing regulatory approvals, CG Oncology represents a compelling investment opportunity for institutional investors interested in pioneering advancements in cancer care.
| Revenue (TTM) | $6.23M |
| Gross Profit (TTM) | $-161.54M |
| EBITDA | $-249.66M |
| Operating Margin | -7468.00% |
| Return on Equity | -26.40% |
| Return on Assets | -17.70% |
| Revenue/Share (TTM) | $0.08 |
| Book Value | $9.33 |
| Price-to-Book | 5.58 |
| Price-to-Sales (TTM) | 1081.53 |
| EV/Revenue | 757.58 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1983.00% |
| Shares Outstanding | $88.64M |
| Float | $68.28M |
| % Insiders | 0.23% |
| % Institutions | 113.25% |
Volatility is currently expanding
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.57 per share a year ago.
CG Oncology is well-positioned to enter a de-risked NMIBC market with cretostimogene, offering a clean tolerability profile and randomized Phase 3 data. CGON's $1B+ cash position funds operations through 2029, with recent ATM activity signaling strong institutional interest rather than funding desperation. PIVOT-006 trial and BLA completion are imminent catalysts; positive results could unlock significant intermediate-risk NMIBC market potential.
DALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. A highly accomplished biopharmaceutical executive with more than 20 years of commercial leadership experience, Ms.
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Bond yields have the entire stock market on edge. The last thing most investors are thinking about is short squeezes, which means maybe they should be something contrarian trades have on their radar.
DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, showing strong efficacy and best-in-class safety versus competitors. Cret achieved a 75% anytime CR, 46% 12-month CR, and 42% 24-month CR in BOND-003 Cohort C, with no Grade 3+ adverse events. Rolling BLA for cret in HR BCG-unresponsive NMIBC is expected to complete in 4Q26, with multiple trial readouts in 2H26 and 2027.
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.54 per share a year ago.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CGON and any ticker you trade — then tracks every position and per-strategy win rate.
